HSTO - Histogen inks license deal with Johns Hopkins University stock rises ~5% after hours
2023-04-03 17:18:03 ET
- Histogen ( NASDAQ: HSTO ) on Monday said it had signed an exclusive license agreement with Johns Hopkins University, sending its shares about 5% higher to $1.25 after hours.
- "The intellectual property associated with this license covers the use of emricasan for the treatment of disease in humans resulting from viral or bacterial infections," the clinical-stage company said in a statement .
- Emricasan is a type of inhibitor called pan-caspase, which is designed to reduce the activities of enzymes that mediate inflammation and the process of programmed cell death.
- Any licensed patents that emerge from the agreement are expected to provide HSTO the freedom to operate and exclusivity for emricasan, the company said.
For further details see:
Histogen inks license deal with Johns Hopkins University, stock rises ~5% after hours